Peter Schmid

910 total citations · 1 hit paper
11 papers, 268 citations indexed

About

Peter Schmid is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Cancer Research. According to data from OpenAlex, Peter Schmid has authored 11 papers receiving a total of 268 indexed citations (citations by other indexed papers that have themselves been cited), including 10 papers in Oncology, 6 papers in Pulmonary and Respiratory Medicine and 4 papers in Cancer Research. Recurrent topics in Peter Schmid's work include HER2/EGFR in Cancer Research (7 papers), Advanced Breast Cancer Therapies (6 papers) and Cancer Immunotherapy and Biomarkers (4 papers). Peter Schmid is often cited by papers focused on HER2/EGFR in Cancer Research (7 papers), Advanced Breast Cancer Therapies (6 papers) and Cancer Immunotherapy and Biomarkers (4 papers). Peter Schmid collaborates with scholars based in United States, United Kingdom and Spain. Peter Schmid's co-authors include Javier Cortés, Wendy Verret, Florence Dalenc, Sara M. Tolaney, Komal Jhaveri, Eva Ciruelos, Aditya Bardia, Oh Kyu Yoon, Olivier Trédan and Frederik Marmé and has published in prestigious journals such as The Lancet, JNCI Journal of the National Cancer Institute and Cancer Research.

In The Last Decade

Peter Schmid

11 papers receiving 268 citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Overall survival with sacituzumab govitecan in hormone receptor-positive and human epidermal growth factor receptor 2-negative metastatic breast cancer (TROPiCS-02): a randomised, open-label, multicentre, phase 3 trial

2023 210 citations Hope S. Rugo, Aditya Bardia et al. The Lancet profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Peter Schmid United States	5	227	113	65	48	27	11	268
T. Valdez United States	6	274 1.2×	153 1.4×	79 1.2×	66 1.4×	40 1.5×	17	326
E.P. Hamilton United States	8	272 1.2×	124 1.1×	91 1.4×	46 1.0×	42 1.6×	29	317
C. Saura Manich Spain	8	229 1.0×	102 0.9×	105 1.6×	58 1.2×	29 1.1×	32	270
Míriam Arumí Spain	5	113 0.5×	80 0.7×	37 0.6×	47 1.0×	33 1.2×	13	172
Marcelle Goldner Cesca Brazil	6	223 1.0×	76 0.7×	88 1.4×	99 2.1×	27 1.0×	18	272
Elisa Minenza Italy	9	182 0.8×	117 1.0×	32 0.5×	31 0.6×	59 2.2×	12	245
Hiroji Iwata Japan	8	192 0.8×	122 1.1×	63 1.0×	43 0.9×	37 1.4×	26	238
Q. Hong United States	6	197 0.9×	96 0.8×	52 0.8×	26 0.5×	46 1.7×	8	239
Hans Wildiers Belgium	4	189 0.8×	79 0.7×	50 0.8×	56 1.2×	30 1.1×	10	233
Brooke Daniel United States	7	170 0.7×	69 0.6×	33 0.5×	58 1.2×	31 1.1×	17	196

Countries citing papers authored by Peter Schmid

Since Specialization

Citations

This map shows the geographic impact of Peter Schmid's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Peter Schmid with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Peter Schmid more than expected).

Fields of papers citing papers by Peter Schmid

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Peter Schmid. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Peter Schmid. The network helps show where Peter Schmid may publish in the future.

Co-authorship network of co-authors of Peter Schmid

This figure shows the co-authorship network connecting the top 25 collaborators of Peter Schmid. A scholar is included among the top collaborators of Peter Schmid based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Peter Schmid. Peter Schmid is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

11 of 11 papers shown

Dent, Rebecca, Javier Cortés, Eva Muñoz‐Couselo, et al.. (2025). Molecular determinants of response to neoadjuvant pembrolizumab plus chemotherapy in patients with high-risk, early-stage, triple-negative breast cancer: exploratory analysis of the open-label, multicohort phase 1b KEYNOTE-173 study. Breast Cancer Research. 27(1). 35–35. 3 indexed citations

Schmid, Peter, Javier Cortés, Rebecca Dent, et al.. (2024). Abstract LBO1-01: Neoadjuvant pembrolizumab or placebo plus chemotherapy followed by adjuvant pembrolizumab or placebo for early-stage triple-negative breast cancer: Updated event-free survival results from the phase 3 KEYNOTE-522 study. Cancer Research. 84(9_Supplement). LBO1–1. 5 indexed citations

Dent, Rebecca, Javier Cortés, Lajos Pusztai, et al.. (2024). Neoadjuvant pembrolizumab plus chemotherapy/adjuvant pembrolizumab for early-stage triple-negative breast cancer: quality-of-life results from the randomized KEYNOTE-522 study. JNCI Journal of the National Cancer Institute. 116(10). 1654–1663. 11 indexed citations

Dent, Rebecca, David W. Cescon, Thomas Bachelot, et al.. (2023). Abstract OT1-03-05: TROPION-Breast02: Phase 3, open-label, randomized study of first-line datopotamab deruxtecan versus chemotherapy in patients with locally recurrent inoperable or metastatic TNBC who are not candidates for anti-PD-(L)1 therapy. Cancer Research. 83(5_Supplement). OT1–3. 4 indexed citations

Rugo, Hope S., Aditya Bardia, Frederik Marmé, et al.. (2023). Overall survival with sacituzumab govitecan in hormone receptor-positive and human epidermal growth factor receptor 2-negative metastatic breast cancer (TROPiCS-02): a randomised, open-label, multicentre, phase 3 trial. The Lancet. 402(10411). 1423–1433. 210 indexed citations breakdown →

Hamilton, Erika, Komal Jhaveri, Sherene Loi, et al.. (2023). Abstract PD18-11: Dose-Expansion Study of Trastuzumab Deruxtecan as Monotherapy or Combined With Pertuzumab in Patients With Metastatic Human Epidermal Growth Factor Receptor 2-Positive (HER2+) Breast Cancer in DESTINY-Breast07 (DB-07). Cancer Research. 83(5_Supplement). PD18–11. 3 indexed citations

Rugo, Hope, Aditya Bardia, Frederik Marmé, et al.. (2023). Abstract GS1-11: Sacituzumab Govitecan (SG) vs Treatment of Physician’s Choice (TPC): Efficacy by Trop-2 Expression in the TROPiCS-02 Study of Patients (Pts) With HR+/HER2– Metastatic Breast Cancer (mBC). Cancer Research. 83(5_Supplement). GS1–11. 18 indexed citations

Turner, Nicholas C., Catey Bunce, Marie Robert, et al.. (2023). Abstract OT1-01-01: A randomised phase II trial of palbociclib and fulvestrant vs standard endocrine therapy in patients with ER positive HER2 negative breast cancer and ctDNA detected molecular relapse during adjuvant endocrine therapy (TRAK-ER). Cancer Research. 83(5_Supplement). OT1–1. 3 indexed citations

McArthur, Heather L., Javier Cortés, Rebecca Dent, et al.. (2023). Abstract PD3-01: Neoadjuvant pembrolizumab + chemotherapy vs placebo + chemotherapy followed by adjuvant pembrolizumab vs placebo for early TNBC: Post hoc analysis of adjuvant radiation therapy in the phase 3 KEYNOTE-522 study. Cancer Research. 83(5_Supplement). PD3–1. 5 indexed citations

10.

Marmé, Frederik, Aditya Bardia, Hope Rugo, et al.. (2023). Abstract P4-07-65: Effect of sacituzumab govitecan vs chemotherapy in HR+/HER2- metastatic breast cancer: patient-reported outcomes from the TROPiCS-02 trial. Cancer Research. 83(5_Supplement). P4–7. 2 indexed citations

11.

Tolaney, Sara M., Peter Schmid, Aditya Bardia, et al.. (2023). Abstract P3-07-08: Exposure-adjusted incidence rates (EAIRs) of adverse events (AEs) from the phase 3 TROPiCS-02 study of sacituzumab govitecan (SG) vs treatment of physician’s choice (TPC) in HR+/HER2- metastatic breast cancer (MBC). Cancer Research. 83(5_Supplement). P3–7. 4 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact